论文部分内容阅读
目的:探讨双联抗血小板治疗急性冠脉综合征(ACS)的临床疗效和安全性。方法:60例ACS患者随机分为治疗组和对照组。对照组给予阿司匹林单抗血小板治疗,治疗组采用阿司匹林+氯吡格雷双联抗血小板治疗,治疗3个月后评价临床疗效。结果:治疗组临床疗效总有效率为93.3%,显著高于对照组(76.7%),相比较有显著性差异(P<0.05);治疗后,两组LVEF、CO、E/A显著上升,与治疗前比较均有显著性差异(P<0.05);且治疗组与对照组比较有显著性差异(P<0.05)。结论:阿司匹林和氯吡格雷双联抗血小板药物治疗ACS,可以强化对血小板聚集的抑制,并增强抗栓效果,值得临床应用。
Objective: To investigate the clinical efficacy and safety of dual antiplatelet therapy for acute coronary syndrome (ACS). Methods: Sixty ACS patients were randomly divided into treatment group and control group. Control group given aspirin monoclonal antibody platelet therapy, the treatment group with aspirin + clopidogrel dual antiplatelet therapy, after 3 months of treatment to evaluate the clinical efficacy. Results: The total effective rate of the treatment group was 93.3%, which was significantly higher than that of the control group (76.7%) (P <0.05). After treatment, the LVEF, CO and E / A of the two groups increased significantly, (P <0.05). There was a significant difference between the treatment group and the control group (P <0.05). Conclusion: Aspirin and clopidogrel dual antiplatelet drugs in the treatment of ACS, can enhance the inhibition of platelet aggregation, and enhance the antithrombotic effect, worthy of clinical application.